# OnCo record inhibrx (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/inhibrx/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "inhibrx" ;
  schema:name "Inhibrx Biosciences"@en ;
  schema:description "Inhibrx Biosciences is a San Diego antibody company testing two cancer drugs: ozekibart, which triggers a self-destruct receptor on tumour cells in bone cancers such as Ewing sarcoma, and an OX40 antibody that boosts immune cells. Sanofi bought its sister lung disease drug in 2024."@en ;
  schema:url <https://onco.cc/companies/inhibrx/>, <https://inhibrx.com/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:citation <https://inhibrx.com/>, <https://inhibrx.com/pipeline/>, <https://www.sec.gov/Archives/edgar/data/1739614/000110465924005727/tm243849d1_ex99-1.htm>, <https://www.sec.gov/Archives/edgar/data/1739614/000110465924066650/tm243190d20_8k.htm> ;
  schema:addressCountry "US" ;
  onco:cancers <https://onco.cc/cancers/sarcoma/> ;
  onco:sections <https://onco.cc/fronts/targeted-therapy/>, <https://onco.cc/fronts/immunotherapy/> ;
  onco:technologies <https://onco.cc/technologies/monoclonal-antibody/> ;
  onco:drugs <https://onco.cc/drugs/inbrx-106/> ;
  onco:trials <https://onco.cc/trials/nct04198766/> .